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Objectives: The cancer multidisciplinary team (MDT)
meeting (MDM) is regarded as the best platform to
reduce unwarranted variation in cancer care through
evidence-compliant management. However, MDMs are
often overburdened with many different agendas and
hence struggle to achieve their full potential. The
authors developed an interactive clinical decision
support system called MATE (Multidisciplinary meeting
Assistant and Treatment sElector) to facilitate explicit
evidence-based decision making in the breast MDMs.
Design: Audit study and a questionnaire survey.
Setting: Breast multidisciplinary unit in a large
secondary care teaching hospital.
Participants: All members of the breast MDT at the
Royal Free Hospital, London, were consulted during
the process of MATE development and
implementation. The emphasis was on acknowledging
the clinical needs and practical constraints of the MDT
and ﬁtting the system around the team’s workﬂow
rather than the other way around. Delegates, who
attended MATE workshop at the England Cancer
Networks’ Development Programme conference in
March 2010, participated in the questionnaire survey.
Outcome measures: The measures included evidence-
compliant care, measured by adherence to clinical
practice guidelines, and promoting research, measured
by the patient identiﬁcation rate for ongoing clinical trials.
Results: MATE identiﬁed 61% more patients who were
potentially eligible for recruitment into clinical trials
than the MDT, and MATE recommendations
demonstrated better concordance with clinical practice
guideline than MDT recommendations (97% of MATE
vs 93.2% of MDT; N¼984). MATE is in routine use in
breast MDMs at the Royal Free Hospital, London, and
wider evaluations are being considered.
Conclusions: Sophisticated decision support systems
can enhance the conduct of MDMs in a way that is
acceptable to and valued by the clinical team. Further
rigorous evaluations are required to examine cost-
effectiveness and measure the impact on patient
outcomes. The decision support technology used in
MATE is generic and if found useful can be applied
across medicine.
PROBLEM STATEMENT
Unwarranted practice variation across
different medical domains has unfortunately
become a pervasive ﬁnding in health service
research, and breast cancer care is no
exception.
1 A recently published study
reported signiﬁcant differences in breast
cancer survival across hospitals in the same
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- How to improve the conduct of a cancer MDT
and standardise decision making in accordance
with best evidence.
- Development and implementation of a novel
clinical decision support (CDS) platform for
breast cancer MDT.
- This study evaluates (1) the concordance
between the CDS suggestions and MDT recom-
mendations and (2) the identiﬁcation rate of
potentially eligible patients for recruiting into the
ongoing research trials, by the MDT and the CDS.
A separate questionnaire survey was conducted
at the national workshop at the Cancer Networks’
Development Programme to get an estimate of
acceptability of such MDT decision support
systems by the cancer networks.
Key messages
- An advanced CDS platform could signiﬁcantly
improve the conduct of cancer MDMs.
- Further robust evaluations are necessary.
Strengths and limitations of this study
- We share our experience of developing an
advanced decision support system and imple-
menting it in a complex clinical environment of
cancer MDT, which was subsequently adopted as
a breast MDMs management tool.
- The results reported here, however encouraging,
are at this point indicative of the potential
beneﬁts but not yet conclusive. They should be
treated with caution until further rigorous
evaluations conﬁrm the effectiveness and
generalisability of the CDS system.
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2 The reasons for prac-
tice variation are multifactorial, and standardisation of
care has been attempted by the introduction of Regional
Cancer Networks in England and the adoption of the
multidisciplinary team (MDT) model to promote
maximal adoption of evidence-based practice. The MDT
model is increasingly being adopted in other non-cancer
medical domains, such as stroke, cardiovascular diseases
and diabetes.
Many beneﬁts of MDTs have been claimed, but few
have been backed by strong evidence.
3 4 However,
despite a signiﬁcant lack of prospective evidence, MDTs
are well accepted in clinical practice; they are regarded
as a major advance in management of patients with
cancer and their use appears to be increasing.
5 As many
healthcare systems have already committed to and
invested in the MDT model, further reductions in
unwarranted variation are likely to be best achieved by
improving their conduct and standardising their deci-
sion-making processes.
6 Data collected by the UK
national cancer peer review programme from over 1000
teams across six cancer types in England indicate that
there is signiﬁcant room for improvement in the
conduct of MDT meetings (MDMs) and show consider-
able variability in the performance of MDTs.
7 A recent
national survey of more than 2000 members of cancer
MDTs demonstrated agreement on the range of criteria
necessary for effective MDT working.
3 A review of the
literature by the authors identiﬁed many pragmatic
challenges and shortcomings in the current conduct of
cancer MDMs summarised in box 1.
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CONTEXT
The Royal Free Hospital NHS Trust (RFH) serves
a population of 2.6 million within the North London
Cancer Network catchment area. The number of new
patients (both benign and cancer) seen as outpatients
by the breast unit in 2009e2010 was 2944. The
Breast Cancer MDT at RFH was established in 2005, in
line with the recommendations of the NHS Cancer
Plan. The MDT uses a set of North London Cancer
Network-approved clinical guidelines and a standardised
minimum data set.
MDMs are held every week in a conventional confer-
ence format (ﬁgure 1). The core members of a breast
MDT include breast surgeons, radiologists, pathologists,
medical and clinical oncologists, plastic surgeons and
breast clinical nurse specialists. A typical breast MDM
discusses an average of 30e40 patients at various stages
in their care pathways every week to decide further
courses of action in their management.
Prior to the introduction of our computer-based
service into the MDMs, an entirely paper-based record
system was used to provide case summaries and to
document the MDT’s discussion and decisions. These
records contained free (unstructured) text rather than
coded and structured data. The trade-offs between
structured (computer interpretable) and unstructured
electronic health records (EHRs) are well known.
9
Recording MDT discussions in an unstructured form,
such as free-text clinical notes, scanned documents, pdfs,
hinders the process of accurate measurement of MDT
performance as computer-based data analysis and
auditing tools cannot be used on unstructured data.
There are many commercially available information
and communication systems, which can assist in the
preparation, presentation and documentation of cases at
the MDMs, such as EHR systems. However, the objectives
of our MDT service improvement exercise was to go
beyond improvements in data management by providing
active support for evidence-based decision making,




Evidence compliant care: adherence with clinical practice
guidelines
With the increasing recognition of shortcomings in
healthcare systems, there is a signiﬁcant cultural and
professional shift towards using evidence-based guid-
ance. Evidence-based standards of care, such as
published practice guidelines and technology assess-
ment reports developed by authoritative organisations,
provide an objective standard against which to assess
MDT decisions. There is growing evidence that use
of evidence-based guidelines can improve patient
outcomes,
11e13 and MDMs provide the best opportunity
to actively promote an appropriate and judicious use of the
guidelines at the point of care.
Promoting research: identiﬁcation of patients eligible for
ongoing research trials
It is widely accepted that recruiting patients into clinical
trials is an effective strategy for ensuring that cancer
patients get the best care as well as providing important
information about the efﬁcacy of treatments. However,
the literature continues to report low rates of accrual
to cancer clinical trials,
14 and many organisations at
national and international levels are investigating strat-
egies for improving accrual rates. Cancer MDMs offer
Box 1 Pragmatic challenges for cancer MDT meetings
1. Ensuring and documenting adherence with standards
(eg, evidence-based guidelines).
2. Identifying patients who are eligible for recruitment into
clinical trials.
3. Ensuring the consistent collection of crucial data, such
as disease staging and outcomes.
4. Establishing robust mechanisms for prospective
assessment of MDT performance.
5. Ensuring MDT recommendations are followed in
practice.
6. Achieving the right balance of educational and care
delivery objectives of this forum.
7. Establishing reliable interfaces with primary care to
ensure continuity of care.
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eligible for participation in clinical trials.
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METHODS
In order to assess the performance of the breast MDTon
the above-mentioned measures, we developed a compu-
terised decision support system, MATE (Multidisci-
plinary meeting Assistant and Treatment sElector), that
captures patient data, identiﬁes eligible patients for
clinical trials and suggests evidence-based treatment
recommendations. MATE also captures MDT decisions
and hence can automatically compare them with
guideline recommendations.
System development
We followed a systematic stepwise approach throughout
the system development lifecycle. Requirements for
MATE were identiﬁed through a systematic review of
the literature
8 and by working closely with members of the
breast MDTat RFH. We adopted the common knowledge
acquisition and design system (CommonKADS) method-
ology to develop a comprehensive process and knowledge
model for breast cancer MDMs.
16 A controlled vocabulary
from the National Cancer Institute thesaurus
17 was used
to facilitate data standardisation. The evidence sources
reviewed included clinical practice guidelines, systematic
reviews and meta-analyses and reports of randomised
controlled trials. Along with the guideline recommenda-
tions, the eligibility criteria of ongoing clinical trials in
breast cancer that were open for recruitment at our
institution were also coded into the system.
PROforma,
18 an established decision modelling
language for modelling clinical decisions and care
pathways, was used to formalise decisions and supporting
evidence in MATE. The PROforma language and appli-
cation development software Tallis used in this project
were originally developed at the Cancer Research UK.
Tallis was used to implement a range of decision support
and other services
i as determined by the requirements
development process outlined above and is used to
update recommendations and other components of the
PROforma knowledge base when new guidance is
published. Tallis is being developed jointly by Oxford
University and the Royal Free development team.
System description
MATE functionality can be categorised under two broad
headings: (1) structured data capture, presentation and
audit, and (2) advanced evidence-based decision
support.
Data capture: MATE allows users to capture detailed
structured clinical data, including, demographics,
comorbidities, test results, clinical ﬁndings, imaging,
pathology and treatment-related data. The data are
entered into the system either before (preparation
phase) or during the MDMs (presentation phase). In the
preparation phase, the data are entered by a clinician,
who is responsible for the preparation of the meeting.
Data entry is ﬂexible, quick and secure, and it was found
to reduce preparation time. If some of the test results
such as pathology reports are not available before the
MDT meeting, they can easily be entered in MATE
during the meeting by a clinician without delaying the
proceedings. MATE also provides patient summaries
automatically and prospective audit facilities.
Advanced evidence-based decision support module: It is the
key component of MATE that sets it apart from cancer
tracking systems, EHR systems and the ﬁrst-generation
decision support, such as rule-based alert and reminder
systems. MATE actively evaluates diagnostic markers
histopathological data and other patient-related factors,
such as co-morbidities to generate patient-speciﬁc
recommendations for clinical management. The Tallis
decision support technology enables MATE to rank the
recommended options: for example, if the ﬁtness of the
Figure 1 MATE (Multidisciplinary meeting Assistant and Treatment sElector) in use at Royal Free breast multidisciplinary team
meeting.
ihttp://mate.cossac.org/.
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recommend the next best option with supporting
evidence. In principle, patient preferences can also be
factored into the MATE decision process and we are
actively exploring ways of doing this in line with widely
discussed needs for greater patient empowerment.
All clinical recommendations made by MATE are
presented to the user together with a summary of the
rationale in the form of arguments and supporting
evidence. The MATE knowledge base has been devel-
oped with reference to a comprehensive set of published
national and international clinical practice guidelines,
which enables MATE to give recommendations even in
complex cases that are covered by these guidelines.
MATE also provides quantitative risk estimates based
on published models as an adjunct to the clinical
recommendations.
The user interface of MATE is illustrated in ﬁgure 2.
The detailed description of the knowledge base,
technology and architecture is published elsewhere.
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Evaluation of concordance between MATE and MDT
recommendations
MATE was used in the background to prospectively
record the proceedings of breast MDMs between April
2008 and July 2009 to gather 1295 cases discussed in the
MDMs during this period (each time a patient was
discussed in the MDT meeting was counted as a separate
encounter). The patient data and the MDT decisions
were entered in MATE during the meeting by the ﬁrst
author. MATE recommendations were not shown to the
MDT to avoid any confounding effect. After the meeting,
the correctness of patient data and MDT recommenda-
tions entered in MATE were cross-checked with the
ofﬁcial paper MDT records by a research associate from
the research team and, in case of any discrepancies, the
patient data and MDT decisions entered in MATE
record data were amended to be in line with the ofﬁcial
MDT record. Approval for an audit study was obtained
from the Research and Development department of the
hospital before starting the study, and data-security
measures such as encryption were put in place.
One of the key features of MATE comparedwith
a traditional EHR is the clinical decision support (CDS)
element. MATE is able to actively evaluate patient data
and to offer guideline-based recommendations in real
time, which are speciﬁc for each individual patient.
We compared MATE recommendations with the MDT
decisions. The discordant cases (where MATE recom-
mendations differed from those of MDT decisions) were
further investigated by a panel who reviewed the
patient’s clinical notes. MATE also automatically ﬂags
Figure 2 Composite screenshot showing the user interface and some of the functionalities of MATE (Multidisciplinary meeting
Assistant and Treatment sElector). Upper left: the summary screen for the patient; upper right: one of the many prognostication
tools available; lower left: decision panel where system recommendations and eligible clinical trials are highlighted in blue; lower
right: the evidential justiﬁcation for each recommended option.
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trials.
Structured feedback from members of cancer networks in
the UK
The MATE development team was invited to conduct
a workshop at the England Cancer Networks’ Develop-
ment Programme conference in March 2010. The
conference was attended by key members from all cancer
networks, who are instrumental in governing and
improving MDT conduct in their respective cancer
networks. MATE was demonstrated in a workshop, and a
questionnaire survey was conducted at the end of
the presentation and discussion session. The aim of the
structured feedback was to gather the views of the
members of cancer networks about the usefulness of
CDS systems in general and MATE in particular, in the
context of cancers MDMS.
Respondents were asked to select from a choice
of ﬁve categories (strongly agree, agree, neutral,
disagree, strongly disagree) for ﬁve structured ques-
tions regarding usefulness of the system. They were
also asked open-ended questions to ﬁnd any perceived
barriers and their general comments. For simplicity,
we have combined ‘strongly agree’ and ‘agree’
responses into an overall ‘agree’ rating and ‘neutral’,
‘disagree’ and ‘strongly disagree’ responses into a
an overall ‘disagree’ rating. The ‘neutral’ category




The case mix of 1295 breast cases included cancers and
benign pathologies. Table 1 shows the overall distribu-
tion of cases recorded on the MATE system during the
study. Metastatic, recurrent and non-epithelial malig-
nancies were excluded from the guideline concordance
analysis as the guidelines and evidence-base for those
subsets were not initially coded in MATE. In 239 cases of
recurrent metastatic or non-epithelial malignancies,
MATE therefore provided data capture services but no
decision support. The remaining 1056 cases were
analysed for concordance between management
recommendations made by MATE and the actual MDT
decisions; the level of concordance was encouragingly
high (93.2%; N¼984). When the 6.8% discordant cases
were further analysed, it was found that in 3.2% cases,
the MDT decisions that differed from MATE recom-
mendations were corrected by the treating clinician in
the results clinic.
MATE also identiﬁed 61% more patients who were
potentially eligible for recruitment into clinical trials
than the MDT alone. Note that MATE only screens the
patients as possibly eligible for the trials, based on the
main eligibility criteria. All the information needed
before recruiting the patient is often not available to the
MDT. Certain tests speciﬁc for the trial (eg, 2D Echo for
ejection fraction) are done after MDT discussion, and
the results are not available at the MDM.
Structured feedback results
The MATE workshop at the Cancer Networks’ Develop-
ment Programme conference was attended by 54 people,
of whom 48 completed the questionnaire. The roles of
respondents were categorised as follows:
Clinicians (Doctors and Nurses) ¼ 13
Patients/survivors ¼ 5
Service improvement managers ¼ 18
Informaticians ¼ 7
Others ¼ 5
There was a very high consensus on the usefulness of
CDS in general, and MATE in particular, for cancer
MDMs. Most respondents (95.8%) agreed that CDS has
a useful role in cancer MDMs. The majority of respon-
dents found the services provided by MATE useful for
the breast MDM (93.47) and potentially for other types
of cancer MDMs (92.6%). The CDS component and
ability to automatically screen patients for ongoing
clinical trials were seen as the two most valuable capa-
bilities of MATE by the majority of respondents (84.5%
and 81.2% of respondents, respectively). Other capabil-
ities of MATE, identiﬁed as valuable were patient data
capture (70% of respondents), clinical audit services
(67%), peer review support (58%) and education/
training (45%). The majority of respondents (73.8%)
were favourable to recommending MATE if it were made
available in their network.
The survey also identiﬁed important barriers to large-
scale deployment of MATE. The main perceived obstacle
to adoption was double data entry (50%) in situations
where existing data capture systems are in place, and it
was suggested that MATE should be able to interface
with existing data capture systems. Other barriers iden-
tiﬁed were costs and resources, clinical buy-in, scalability
and the need for appropriate knowledge maintenance
mechanisms that can cope with the large volumes of
clinical evidence.
CHALLENGES AND NEXT STEPS
We wish to emphasise that the role of MATE or any
similar IT system is purely supportive and the MDT
meeting continues to be led by the clinical team.
Table 1 Distribution of breast cases discussed at MDM
according to type
Pathology Number
Benign breast disease 413
Operable breast cancer (in situ and invasive) 511
No ﬁnal diagnosis reached (eg, C1/C3/C4 on
cytology or B1/B3/B4 on core biopsy) at the
time of MDT meeting
132
Metastatic and/or recurrent cancers 198
Other than breast epithelial malignancies 41
Total cases 1295
MDT, multidisciplinary team; MDM, MDT meeting.
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and functional MDT
20 and cannot compensate for
inherent weaknesses in team composition, organisation
or operation. The preliminary audit results and the
qualitative assessment data reported in this study,
however encouraging, are at this point indicative of the
potential beneﬁts but not yet conclusive until further
rigorous evaluations conﬁrm the effectiveness and
generalisability of MATE or similar services.
Generalisability
It has been reported that CDS systems produce better
results when the developing team is also responsible for
the trial of the system. One review reported, for
example, that the success rate for CDS systems dropped
from 74% to 28% when the systems were tested by
independent teams.
21 The team involved in the devel-
opment of MATE was also involved in testing and the
deployment of the system so replication of our results on
other sites is a key objective. It was for the same reason
that the questionnaire survey from the user was not
conducted at this stage, and this is planned during the
wider implementation phase. Demonstrating that MATE
can confer signiﬁcant beneﬁts for other cancer MDTs is
also a high priority. MATE has attracted the attention of
the UK Department of Health’s National Cancer Action
Team, and deployment of the system in other NHS trusts
is being explored.
Effectiveness trials
Deﬁnitive evidence of the value of complex (multifac-
eted) interventions such as MATE requires a multicentre
trial in which a cluster randomised design is likely to be
the preferred methodology.
22 The trial should look into
all important impacts of the intervention, including
quantitative measures of cost, patient outcomes and
process measures as well as qualitative measures.
Patient empowerment
Patient involvement in decisions about their treatment
is widely considered to be crucial to improving
outcomes, and many cancer patients wish to play a more
active role in their care. The current structure of the
cancer MDT meeting makes patient participation very
difﬁcult to achieve.
23 We are therefore exploring ways in
which MATE could facilitate patient engagement, by
extending access to certain of its functions by the
patients. This could be achieved in a variety of settings,
including consultations in results clinic and from the
patient’s home using the internet, allowing the patients
to review their clinical history, the MDT recommenda-
tions and the reasons and justifying evidence for those
recommendations.
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